Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[P-pills and thrombosis]

O Lidegaard1

  • 1Gynaekologisk-obstetrisk afd, Herlev Amtssygehus.

Nordisk Medicin
|July 4, 1998
PubMed
Summary
This summary is machine-generated.

Oral contraceptives (OCs) carry a slightly increased risk of thrombosis. Newer low-dose formulations with third-generation progestagens may offer a safer profile for arterial thrombosis risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical associations versus causal inference.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Prediction of preterm pre-eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to 2017.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2021
Same author

Corrigendum. Imprinting disorders in children born after ART: a Nordic study from the CoNARTaS group.

Human reproduction (Oxford, England)·2021
Same author

Cancer in pregnancy increases the risk of venous thromboembolism: a nationwide cohort study.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Imprinting disorders in children born after ART: a Nordic study from the CoNARTaS group.

Human reproduction (Oxford, England)·2020
Same author

Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort.

BJOG : an international journal of obstetrics and gynaecology·2018

Area of Science:

  • Reproductive Health
  • Pharmacology
  • Thrombosis Research

Context:

  • Oral contraceptives (OCs) are widely used for birth control.
  • Recent studies have investigated the epidemiological, clinical, and metabolic aspects of thrombosis associated with OC use.
  • Changes in OC formulation, particularly estrogen content and progestagen generation, influence thrombotic risk.

Purpose:

  • To review the current understanding of thrombosis risk associated with oral contraceptive usage.
  • To compare the risks of arterial and venous thrombosis between different generations of progestagens in low-dose OCs.
  • To provide guidance on OC selection for women with varying thrombotic risk profiles.

Summary:

  • Low-dose OCs with reduced estrogen content show a 1.5-3 fold increased risk of myocardial or cerebral thrombosis.

Related Experiment Videos

  • Third-generation progestagen OCs appear to have a lower risk of infarction and possibly cerebral thrombosis compared to second-generation.
  • Venous thrombosis risk is elevated 2-4 fold with second-generation and 3-5 fold with third-generation progestagen OCs, though clinical significance varies.

    • Impact:

    • Prescribing low-dose OCs with second-generation progestagens is recommended for women at increased risk of venous thrombosis.
    • For women at increased risk of arterial thrombosis, OCs with third-generation progestagens are a reasonable first choice.
    • Women without a predisposition to thrombosis can safely use any low-dose OC formulation.